A direct comparison of sodium stibogluconate treatment in two animal models of human visceral leishmaniasis, mouse and hamster
- 1 July 1989
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 53 (2) , 129-137
- https://doi.org/10.1016/0378-5173(89)90236-6
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infectionInternational Journal of Pharmaceutics, 1989
- The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependentJournal of Pharmacy and Pharmacology, 1988
- Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeysAntimicrobial Agents and Chemotherapy, 1986
- Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconateJournal of Pharmacy and Pharmacology, 1986
- Liposomes as drug carriers in leishmaniasis and malariaParasitology Today, 1986
- Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamstersPathogens and Global Health, 1984
- Genetic control of recovery from visceral leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Liposomes in leishmaniasis: Therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracyclineLife Sciences, 1980
- Influence of H–2 complex on acquired resistance to Leishmania donovani infection in miceNature, 1980
- Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drugLife Sciences, 1978